Westfield Bank
Total Consideration
$324.4M
2 years of history · ending 2025-12-31 · SEC EDGAR
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | — | — | — | 1.00% | 0.60% | 1.30% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | — | — | — | 0.20% | 0.00% | 0.30% |
| Nondeductible Expenses | — | — | — | -0.10% | 0.20% | 0.70% |
| Tax Law Change | — | — | — | — | — | — |
| Effective Tax Rate | — | — | — | 19.70% | 14.70% | 20.40% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | $28.6M | $35.8M | $24.1M | $62.7M | $39.5M | $65.7M |
| Income Taxes Paid (Cash) | — | — | — | $10.1M | $27.5M | $9.2M |
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.
Total Consideration
$324.4M
Phase 1: currency selection stored in the URL. Conversion ships in Phase 2 (see ADR-0003).